Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Inclusion Criteria: * Requires treatment with IV antibiotic therapy for hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) * Fulfills clinical and radiographic criteria, with onset of criteria occurring after more than 48 hours of hospitalization or within 7 days after discharge from a hospital (for HABP); or at least 48 hours after mechanical ventilation (for VABP) * Has an adequate baseline lower respiratory tract specimen obtained for Gram stain and culture * Has an infection known or thought to be caused by microorganisms susceptible to the IV study therapy * Agrees to allow any bacterial isolates obtained from protocol-required specimens related to the current infection to be provided to the Central Microbiology Reference Laboratory for study-related microbiological testing, long term storage, and other future testing * Is not of reproductive potential; or if of reproductive potential agrees to avoid impregnating a partner or avoid becoming pregnant, by practicing abstinence or using acceptable contraception Exclusion Criteria: * Has a baseline lower respiratory tract specimen Gram stain that shows the presence of Gram-positive cocci only * Has confirmed or suspected community-acquired bacterial pneumonia (CABP) * Has confirmed or suspected pneumonia of viral, fungal or parasitic origin * Has HABP/VABP caused by an obstructive process, including lung cancer or other known obstruction * Has a carcinoid tumor or carcinoid sy…